Search results for Amatuximab
Amatuximab Biosimilar – Anti-MSLN mAb – Research Grade, ProteoGenix, PX-TA1049
Description of Amatuximab Biosimilar - Anti-MSLN mAb - Research Grade Introduction to Amatuximab Biosimilar – A Promising Anti-MSLN mAb Amatuximab Biosimilar, also known as Anti-MSLN mAb, is a monoclonal antibody (mAb) that has shown promising results in the treatment of various cancers. This biosimilar version of the original Amatuximab has been developed to provide a more affordable and accessible option for patients. In this article, we will delve into the structure, activity, and potential applications of Amatuximab Biosimilar. Structure of Amatuximab Biosimilar Amatuximab Biosimilar is a recombinant humanized IgG1 monoclonal antibody that has been designed to target the mesothelin (MSLN) protein. The antibody has a molecular weight of approximately 150 kDa and is composed of two heavy chains and two light chains. The heavy chains consist of four constant domains (CH1, CH2, CH3, and CH4) and one variable domain (VH), while the light chains consist of two constant domains (CL and CL2) and one variable domain (VL). The variable domains of Amatuximab Biosimilar are responsible for binding to MSLN, while the constant domains are responsible for mediating effector functions such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). The antibody has been engineered to have a longer half-life and improved binding affinity compared to the original Amatuximab, making it a more potent therapeutic agent. Activity of Amatuximab Biosimilar Amatuximab Biosimilar works by targeting the MSLN protein, which is overexpressed in various cancers, including mesothelioma, ovarian cancer, and pancreatic cancer. MSLN is a cell surface glycoprotein that plays a crucial role in cell adhesion, proliferation, and invasion. By binding to MSLN, Amatuximab Biosimilar inhibits these processes and induces cell death through various mechanisms. One of the main mechanisms of action of Amatuximab Biosimilar is ADCC, where the antibody binds to MSLN-expressing cancer cells and recruits immune cells, such as natural killer (NK) cells, to kill the target cells. The antibody also activates the complement system, leading to the formation of membrane attack complexes that can directly kill cancer cells. Title: Potential Applications of Amatuximab Biosimilar Amatuximab Biosimilar has shown promising results in preclinical and clinical studies for the treatment of various cancers. In particular, it has shown efficacy in mesothelioma, a rare and aggressive cancer that is often resistant to chemotherapy. The antibody has also shown potential in other MSLN-expressing cancers, such as ovarian and pancreatic cancer. Currently, Amatuximab Biosimilar is being evaluated in phase II clinical trials for the treatment of mesothelioma and ovarian cancer. The results from these trials have shown promising efficacy and safety profiles, with some patients experiencing partial or complete remission. If these trials are successful, Amatuximab Biosimilar could potentially become a valuable treatment option for patients with these types of cancers. Conclusion In conclusion, Amatuximab Biosimilar is a promising anti-MSLN mAb that has been developed as a biosimilar version of the original Amatuximab. Its unique structure and activity make it a potent therapeutic agent for various MSLN-expressing cancers. With ongoing clinical trials, Amatuximab Biosimilar has the potential to become a valuable treatment option for patients in need.
Host
Reactivity
Applications
Conjugation
Amatuximab, Abbexa, abx831015
Amatuximab is a monoclonal antibody biosimilar expressed in CHO cells, targeting MSLN, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Amatuximab has been used in trials studying the treatment and basic science of Mesothelioma, Ovarian Cancer, Ovarian Neoplasms, Pancreatic Cancer, and Mesothelioma, Malignant, among others.
Host
Human, Mouse
Reactivity
Human
Applications
ELISA, WB
Conjugation
Unconjugated
Amatuximab ELISA Kit, ProteoGenix, KPTX246
Description of Amatuximab ELISA Kit Introduction Amatuximab, also known as MORAb-009, is a monoclonal antibody that has shown promising results in the treatment of various types of cancer. It specifically targets mesothelin, a protein that is overexpressed in many types of cancer cells. The Amatuximab ELISA Kit is a valuable tool for researchers and clinicians to measure the levels of Amatuximab in patient samples and monitor its activity. Structure of Amatuximab Amatuximab is a chimeric monoclonal antibody, meaning it is composed of both human and mouse components. It is made up of two heavy chains and two light chains, with a total molecular weight of approximately 150 kDa. The heavy chains are composed of constant and variable regions, while the light chains only have variable regions. The variable regions are responsible for binding to the target protein, mesothelin. Activity of Amatuximab As mentioned earlier, Amatuximab specifically targets mesothelin, a protein that is highly expressed in various types of cancer cells. Mesothelin is a glycoprotein that is normally found on the surface of mesothelial cells, but its expression is significantly increased in cancer cells. Amatuximab binds to mesothelin with high affinity, blocking its activity and preventing its interaction with other proteins. This results in inhibition of cancer cell growth and induction of cell death, making Amatuximab a promising therapeutic agent for cancer treatment. Application of Amatuximab ELISA Kit The Amatuximab ELISA Kit is a valuable tool for measuring the levels of Amatuximab in patient samples. It is a highly sensitive and specific assay that utilizes the sandwich ELISA technique. The kit contains all the necessary reagents and materials for the quantification of Amatuximab, including pre-coated microplates, detection and capture antibodies, and standards. The procedure is simple and can be completed within a few hours, making it suitable for high-throughput analysis. The Amatuximab ELISA Kit has various applications in both research and clinical settings. In research, it can be used to evaluate the pharmacokinetics and pharmacodynamics of Amatuximab, as well as its efficacy in different cancer models. It can also be used to study the expression levels of mesothelin in various cancer types and its correlation with Amatuximab response. In clinical settings, the kit can be used to monitor Amatuximab levels in patient samples, ensuring proper dosing and treatment efficacy. It can also be used as a diagnostic tool to determine the presence of mesothelin in cancer patients, which can help in patient selection for Amatuximab treatment. Advantages of Amatuximab ELISA Kit The Amatuximab ELISA Kit offers several advantages over other methods of Amatuximab detection. First and foremost, it is highly specific and sensitive, allowing for accurate quantification of Amatuximab levels in patient samples. It also has a wide dynamic range, making it suitable for measuring both high and low concentrations of Amatuximab. The kit is also cost-effective and time-efficient, making it a preferred choice for researchers and clinicians. Conclusion The Amatuximab ELISA Kit is a valuable tool for measuring the levels of Amatuximab in patient samples. It is a highly specific and sensitive assay that utilizes the sandwich ELISA technique. Amatuximab, a chimeric monoclonal antibody, specifically targets mesothelin, a protein that is overexpressed in many types of cancer cells. The Amatuximab ELISA Kit has various applications in research and clinical settings, making it a valuable asset in the development and monitoring of Amatuximab as a therapeutic agent for cancer treatment.
Host
Reactivity
Applications
Conjugation
Amatuximab ELISA Kit, Abbexa, abx395135
Amatuximab ELISA Kit is a quantitative ELISA kit for detection of Amatuximab.Amatuximab, alternative names: MORAb-009, anti-MSLN monoclonal antibody (MAb) is a chimeric, humanized IgG1/k MAb that targets the cell surface Mesothelin (MSLN). The precursor of MORAb-009 was isolated by Chowdhury et al in 1998 56 from a mouse splenic mRNA and was then optimized by fusing the gene encoding MSLN Fv (SS1 scFv) with human IgG1 and kappa regions. It was first designed to treat patients with mesothelin-positive cancers (pancreatic, ovarian, mesothelioma and lung). Amatuximab is not yet commercially available, and the highest development phase is Phase II. In addition, on 16 January 2014, orphan designation (EU/3/13/1222) was granted by the European Commission to Eisai Europe Limited, United Kingdom, for amatuximab for the treatment of malignant mesothelioma.
Host
Reactivity
Human
Applications
ELISA
Conjugation
Amatuximab Biosimilar - Research Grade, ichor.bio, ICH5069
Detects human MSLN. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Amatuximab.
Host
CHO Cells
Reactivity
Human
Applications
Conjugation
Please provide the required information below so that we can quickly source your products.